文献速递中医内科中药与中成药合理使用

加减中药复方通过调节肠道菌群增强抗动脉粥样硬化药理效应

The Enhanced Pharmacological Effects of Modified Traditional Chinese Medicine in Attenuation of Atherosclerosis Is Driven by Modulation of Gut Microbiota.
PubMed 文献 · Front Pharmacol · 2020-10-15

该研究在大鼠高脂饮食诱导的动脉粥样硬化模型中系统比较通脉逐瘀(TMZY)、血府逐瘀(XFZY)与阿托伐他汀的药理效应,TMZY在病理形态、免疫组化和炎症因子等方面表现更优;TMZY联合阿托伐他汀可进一步抑制免疫炎症反应。研究进一步用高胆碱饮食小鼠及16S扩增子测序发现,TMZY比XFZY引起更多肠道菌群改变,且抗生素抑制肠道微生物活性后TMZY的干预效应减弱。

要点

  • TMZY在改善AS大鼠病理形态、免疫组化及炎症因子方面优于XFZY和阿托伐他汀。
  • TMZY联合阿托伐他汀可进一步抑制免疫与炎症反应,缓解AS。
  • TMZY的效应依赖肠道菌群调控,抗生素抑制菌群活性后效应减弱。

核心结论

  • 中药复方可通过调节肠道菌群改变心血管疾病发病机制,TMZY较XFZY调节更多菌群改变并改善疾病表型。

研究设计与样本

  • 研究先在大鼠高脂饮食诱导的AS模型中评估TMZY、XFZY与阿托伐他汀的药理效应。
  • 随后用高胆碱饮食诱导的AS小鼠,在抗生素处理与未处理条件下以16S扩增子测序分析肠道菌群变化。

主要发现

  • TMZY在病理形态、免疫组化和炎症因子等方面通常优于XFZY和阿托伐他汀。
  • TMZY联合阿托伐他汀可进一步通过抑制免疫和炎症反应缓解大鼠AS。
  • TMZY比XFZY引起更多肠道菌群改变以改善疾病表型。
  • 抗生素抑制肠道微生物活性后,TMZY对小鼠CVD的干预效应减弱。

临床怎么用

  • 对动脉粥样硬化患者,可考虑在阿托伐他汀基础上联合TMZY以增强免疫炎症抑制效果。
  • TMZY的临床效应可能部分依赖肠道菌群状态,使用抗生素或菌群紊乱时需评估其疗效。

局限性

  • 机制与疗效证据主要来自高脂饮食大鼠和高胆碱饮食小鼠模型,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accumulating evidence indicated that gut microbiota-targeted therapy is a promising strategy to treat Cardiovascular Disease (CVD). Traditional Chinese Medicine (TCM) has been used in CVD treatments for over 2,000 years which is believed to result from the modulation of gut microbiota, yet the underlying mechanism remains elusive. According to the theoretical system of TCM, we developed an innovative formula of TCM named "TongMai ZhuYu (TMZY)" on top of one classic Chinese herbal formula ["XueFu ZhuYu (XFZY)"], which can more effectively alleviate CVD in the clinical practice. Here, we first systematically assessed the pharmacological effects of TMZY, XFZY, and atorvastatin on atherosclerosis (AS) induced by high-fat diet (HFD) in rats. TMZY typically outperformed others in alleviating AS rats by characterization of pathological morphology, immunohistochemistry, inflammatory cytokines. Remarkably, combining this modified TCM formula (TMZY) with atorvastatin can further help the alleviation of AS in rats by suppressing immune and inflammatory responses. Furthermore, to test whether TMZY alleviated AS symptoms by altering gut microbial compositions (dysbiosis), we employed 16S amplicon sequencing to investigate gut microbiota changes in the AS mice induced by high choline diet (HCD) using both TMZY and XFZY under antibiotic-treated and untreated conditions. TCM formulas induced consistent and remarkable changes in the phenotypes and microbiota in the HCD mice. TMZY modulated more changes in the gut microbiota to improve diseased phenotypes than XFZY. Notably, the TMZY-intervention effect on CVD in mice attenuated after the suppression of gut microbial activity by antibiotics. Collectively, we demonstrated that TCM herbals could effectively modulate the gut microbiota as a mechanism for altering the pathogenesis of cardiovascular disorders in mice/rats.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ji W, Jiang T, Sun Z, et al. The Enhanced Pharmacological Effects of Modified Traditional Chinese Medicine in Attenuation of Atherosclerosis Is Driven by Modulation of Gut Microbiota. Front Pharmacol. 2020. PMID: 33178012. doi:10.3389/fphar.2020.546589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。